10.00EUR0.00%Mkt Cap: 19.99M EURP/E: 1.84Last update: 2026-05-14
Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical dev…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)1.84
P/E (Forward)4.37
PEG—
P/B-3.27
P/S2.51
EV/EBITDA604.11
EV/Revenue3.64
EPS (TTM)5.44
EPS (Forward)2.29
Cash Flow & Leverage
FCF Yield-9.55%
FCF Margin-23.98%
Operating CF-2.40M EUR
CapEx (TTM)—
Net Debt/EBITDA220.92
Net Debt10.61M EUR
Technical
SMA 5013.98 (-28.5%)
SMA 20018.08 (-44.7%)
Beta-0.16
S&P 52W Chg24.23%
Avg Vol (30d)10.21K
Avg Vol (10d)11.22K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—
52W Range
9.50062% of range10.30
52W High10.30 EUR
52W Low9.500 EUR
Profitability
Gross Margin20.64%
EBITDA Margin0.60%
Profit Margin-324.76%
Oper. Margin-427.74%
ROE58.93%
ROA-188.39%
Revenue Growth-76.90%
Earnings Growth—
Balance Sheet
Debt/Equity-1.08
Current Ratio0.25
Quick Ratio0.22
Book Value/Sh-3.0580 EUR
Cash/Share0.5170 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.2.00M
Float1.32M
Insiders24.30%
Institutions17.30%
Analyst Consensus
Rating—
Target (Mean)50.50 EUR
Target Range50.00 EUR – 51.00 EUR
# Analysts2
Company
Market Cap19.99M EUR
Enterprise Value29.01M EUR
Revenue (TTM)7.96M EUR
Gross Profit979.99K EUR
Net Income (TTM)-15.42M EUR
Revenue/Share4.326 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees32
Last Price10.00 EUR
CountryAT
SectorHealthcare
IndustryBiotechnology
ISINATMARINOMED6